ArticlePloS one2021
Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Serum and Nasal Lavage Fluid Eosinophil-Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes.Clinical and translational allergy · 2026Article
- Associations Between Different Eosinophil Activity Markers and Clinical Outcomes in Young Asthmatics.Clinical and translational allergy · 2026Article
- Eosinophil-Derived Neurotoxin: A Potential Biomarker for Allergic Bronchopulmonary Aspergillosis.Journal of asthma and allergy · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Electroacupuncture as an eosinophil-targeting treatment in ovalbumin-induced allergic rhinitis involving βFrontiers in immunology · 2026Article
- Molecular Mechanisms Linking Eosinophils to Lung Function Impairment in Respiratory Diseases.Journal of asthma and allergy · 2026Review
- From FEVJournal of asthma and allergy · 2026Review
- Elevated plasma eosinophil-derived neurotoxin is associated with echocardiographic pulmonary vascular involvement in stable COPD.Frontiers in medicine · 2026Article
- Characteristics related to biomarkers of neutrophil, eosinophil, and mast cell activation.Scientific reports · 2025Article
- Serum and nasal lavage fluid eosinophil-derived neurotoxin levels and their determinants in adults.The journal of allergy and clinical immunology. Global · 2025Article
- Eosinophil-derived neurotoxin levels can predict allergic disease development and atopic march in children.Clinical and experimental pediatrics · 2025Article
- Serum and urine eosinophil-derived neurotoxin (EDN) levels predict biologic response in severe asthma.The World Allergy Organization journal · 2025Article
- Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view.Frontiers in allergy · 2025Article
- Eosinophil-Derived Neurotoxin Determinants and Reference Values in a Swedish Middle-Aged General Population.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Lung Gene Expression Suggests Roles for Interferon-Stimulated Genes and Adenosine Deaminase Acting against RNA-1 in Pathologic Responses to Diisocyanate.Chemical research in toxicology · 2024Article
- Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.Asia Pacific allergy · 2024Review
- Eosinophil granule proteins as a biomarker in managing asthma and allergies.Asia Pacific allergy · 2023Review
- Eosinophil Granule Proteins Involvement in Acute Appendicitis-An Allergic Disease?International journal of molecular sciences · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing body of evidence for the utility of eosinophil-derived neurotoxin (EDN) as a biomarker in asthma, including association with eosinophilic airway inflammation, assessment of disease severity and potential for predicting pathogenic risks, including exacerbations. However, to interpret any biomarker data with confidence, it is first important to understand the preanalytical factors and biological variation that may affect its reliable measurement and results interpretation. In this study we defined the healthy serum EDN reference range for men and women as 1.98 to 26.10 ng/mL, with no significant gender differences. Smoking did not impact the mean EDN levels and no circadian rhythm was identified for EDN, unlike blood eosinophils (EOS) where levels peaked at 00:00h. EDN expression in different cell types was investigated and shown to occur primarily in eosinophils, indicating they are likely to be the main cellular repository for EDN. We also confirm that the quantification of serum EDN is not influenced by the type of storage tube used, and it is stable at ambient temperature or when refrigerated for at least 7 days and for up to one year when frozen at -20°C or -80°C. In summary, EDN is a stable biomarker that may prove useful in precision medicine approaches by enabling the identification of a subpopulation of asthma patients with activated eosinophils and a more severe form of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.